<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485691</url>
  </required_header>
  <id_info>
    <org_study_id>LPS14201</org_study_id>
    <secondary_id>2014-004676-29</secondary_id>
    <secondary_id>U1111-1166-5329</secondary_id>
    <nct_id>NCT02485691</nct_id>
  </id_info>
  <brief_title>Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent</brief_title>
  <acronym>CARD</acronym>
  <official_title>A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To compare the radiographic progression-free survival (rPFS) of chemotherapy (cabazitaxel
      plus prednisone, Arm A) versus AR-targeted therapy (enzalutamide or abiraterone acetate plus
      prednisone, Arm B) in mCRPC patients who have been treated with docetaxel and who had disease
      progression while receiving AR-targeted therapy within 12 months of AR treatment initiation
      (â‰¤12 months, either before or after docetaxel).

      Secondary Objectives:

        -  To compare efficacy for:

        -  Prostate-specific antigen (PSA) response rate and time to PSA progression (TTPP).

        -  Progression-free survival (PFS).

        -  Overall survival (OS).

        -  Tumor response rate and duration of tumor response.

        -  Pain response and time to pain progression.

        -  Symptomatic skeletal event (SSE) rate and time to occurrence of any SSE.

        -  Health status and Health-related Quality of Life (HRQOL).

        -  To evaluate the correlation of a signature of resistance to AR-targeted agents with
           clinical outcome via the analysis of circulating tumor cell (CTC) phenotypes as well as
           expression and localization of proteins including AR isoforms in CTCs.

        -  To evaluate safety in the 2 treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study per patient will be approximately 2 years. Each patient will be
      treated until radiographic disease progression, unacceptable toxicity, or patient's refusal
      of further study treatment, and each patient will be followed after completion of study
      treatment until death, study cutoff date, or withdrawal of patient consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2015</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic progression-free survival defined as the time from randomization to the occurrence of radiological tumor progressions using RECIST 1.1 and PCWG2 criteria</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic progression-free survival defined as the time from randomization to the occurrence of death due to any cause</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving PSA decline &gt;=50%</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival-Time</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival defined as the time interval from the date of randomization to the date of death due to any cause</measure>
    <time_frame>Up to 2 years posttreatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression defined as the time interval between the date of randomization and the date of PSA progression using PCWG2 definition</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving tumor response</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of tumor response</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain response using Brief Pain Inventory-Short Form (BPI-SF) for pain intensity score</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic skeletal event (SSE) rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of HRQOL using the Functional Assessment of Cancer Therapy - Prostate (FACT-P) scale</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of health status using the 5-Level EuroQol Group's 5-Dimension (EQ-5D-5L) questionnaire</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 30 days after the last treatment administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 25 mg/m^2 intravenously in 1 hour every 3 weeks + prednisone 10 mg orally given daily + Primary prophylactic G-CSF (the choice of the G-CSF product is left to the Investigator's decision). Treatment will continue until confirmed disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone acetate or enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abiraterone acetate oral 1000 mg once daily continuously + prednisone 5 mg orally given twice daily OR enzalutamide oral 160 mg once daily continuously. Treatment will continue until confirmed disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabazitaxel XRP6258</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzalutamide</intervention_name>
    <description>Pharmaceutical form:capsule Route of administration: oral</description>
    <arm_group_label>Abiraterone acetate or enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone acetate</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Abiraterone acetate or enzalutamide</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_label>Abiraterone acetate or enzalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically or cytologically confirmed prostate adenocarcinoma.

          -  Metastatic disease.

          -  Effective castration with serum testosterone levels &lt;0.5 ng/mL.

          -  Progressive disease defined by at least one of the following:

          -  Progression in measurable disease (Response Evaluation Criteria in Solid Tumors
             [RECIST] 1.1 criteria).

          -  Appearance of 2 or more new bone lesions (Prostate Cancer Working Group 2 [PCWG2]).

          -  Rising PSA (PCWG2).

          -  Having received prior docetaxel for at least 3 cycles (before or after an AR-targeted
             therapy). Docetaxel administration in combination with androgen deprivation therapy
             (ADT) in metastatic hormone-sensitive disease is considered a prior exposure.
             Docetaxel rechallenge is allowed.

          -  Having progressive disease (PD) while receiving AR-targeted therapy with abiraterone
             acetate or enzalutamide within 12 months of AR treatment initiation (â‰¤12 months).

          -  A PSA value of at least 2 ng/mL is required at study entry.

          -  Prior AR-targeted therapy (abiraterone acetate or enzalutamide) must be stopped at
             least 2 weeks before study treatment.

          -  Signed informed consent.

        Exclusion criteria:

          -  Prior chemotherapy other than docetaxel for prostate cancer, except estramustine and
             except adjuvant/neoadjuvant treatment completed &gt;3 years ago.

          -  Less than 28 days elapsed from prior treatment with chemotherapy, immunotherapy,
             radiotherapy, or surgery to the time of randomization.

          -  Adverse events (excluding alopecia and those listed in the specific exclusion
             criteria) from any prior anticancer therapy of Grade &gt;1 (National Cancer Institute
             Common Terminology Criteria [NCI CTCAE] v4.0) at the time of randomization.

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) &gt;2 (ECOG 2 must be
             related to prostate cancer, not to other comorbidities).

          -  Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial
             (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which
             treatment has been completed â‰¥5 years ago and from which the patient has been
             disease-free for â‰¥5 years.

          -  Participation in another clinical trial and any concurrent treatment with any
             investigational drug within 30 days prior to randomization.

          -  Acquired immunodeficiency syndrome (AIDS-related illnesses) or known human
             immunodeficiency virus (HIV) disease requiring antiretroviral treatment.

          -  Patients with reproductive potential who do not agree, in conjunction with their
             partner, to use accepted and effective method of contraception during the study
             treatment period and up to 6 months after the last administered dose. The definition
             of &quot;effective method of contraception&quot; described hereafter: oral contraceptives,
             combined hormonal intravaginal, transdermal, or intra uterine device or will be based
             on country-specific regulatory requirements, and documented in the Informed Consent
             Form.

          -  Known allergies, hypersensitivity or intolerance to prednisone or excipients of
             abiraterone acetate, enzalutamide, docetaxel, or polysorbate 80.

          -  Known history of mineralocorticoid excess or deficiency.

          -  History of seizure, underlying brain injury with loss of consciousness, transient
             ischemic attack within the past 12 months, cerebral vascular accident, brain
             arteriovenous malformation, brain metastases, or the use of concomitant medications
             that may lower the seizure threshold.

          -  Unable to swallow a whole tablet or capsule.

          -  Inadequate organ and bone marrow function as evidenced by:

          -  Hemoglobin &lt;10.0 g/dL;

          -  Absolute neutrophil count &lt;1.5 Ã— 10^9/L;

          -  Platelet count &lt;100 Ã— 10^9/L;

          -  Aspartate aminotransferase/serum glutamic oxaloacetic transaminase and/or alanine
             aminotransferase/serum glutamic pyruvic transaminase &gt;1.5 Ã— the upper limit of normal
             (ULN);

          -  Total bilirubin &gt;1.0 Ã— ULN;

          -  Potassium &lt;3.5 mmol/L;

          -  Child-Pugh Class C.

          -  Contraindications to the use of corticosteroid treatment.

          -  Symptomatic peripheral neuropathy Grade â‰¥2 (NCI CTCAE v4.0).

          -  Uncontrolled severe illness or medical condition including uncontrolled diabetes
             mellitus, history of cardiovascular disease (uncontrolled hypertension, arterial
             thrombotic events in the past 6 months, congestive heart failure, severe or unstable
             angina pectoris, recent myocardial infarction within the last 6 months, or
             uncontrolled cardiac arrhythmia).

          -  Concomitant vaccination with yellow fever vaccine.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 040002</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040003</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040004</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056013</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056011</name>
      <address>
        <city>Brugge</city>
        <zip>B-8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056007</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056003</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056002</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056006</name>
      <address>
        <city>Charleroi</city>
        <zip>BE-6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056005</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056010</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056008</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203005</name>
      <address>
        <city>Brno</city>
        <zip>65653</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203001</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203002</name>
      <address>
        <city>Plzen</city>
        <zip>30460</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203003</name>
      <address>
        <city>Praha 4</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250012</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250010</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250006</name>
      <address>
        <city>LYON Cedex 8</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250019</name>
      <address>
        <city>Lyon</city>
        <zip>69009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250004</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250011</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>PARIS Cedex 15</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250013</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250007</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250014</name>
      <address>
        <city>Plerin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250016</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250018</name>
      <address>
        <city>Saint-MandÃ©</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250009</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250005</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250008</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276028</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276027</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276008</name>
      <address>
        <city>Berlin</city>
        <zip>14179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276022</name>
      <address>
        <city>Duisburg</city>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276013</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276016</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276023</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276002</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276007</name>
      <address>
        <city>GÃ¶ttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276009</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276017</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276026</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276012</name>
      <address>
        <city>KÃ¶ln</city>
        <zip>50968</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276004</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276019</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276018</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276006</name>
      <address>
        <city>MÃ¼nster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276003</name>
      <address>
        <city>NÃ¼rtingen</city>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276010</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276024</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276011</name>
      <address>
        <city>TÃ¼bingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276020</name>
      <address>
        <city>Wuppertal</city>
        <zip>42103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300001</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300002</name>
      <address>
        <city>Athens</city>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300005</name>
      <address>
        <city>Marousi, Athens</city>
        <zip>15125</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300004</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 352001</name>
      <address>
        <city>Reykjavik</city>
        <zip>101</zip>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 372001</name>
      <address>
        <city>Dublin 24</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 372003</name>
      <address>
        <city>Dublin 7</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 372004</name>
      <address>
        <city>Dublin</city>
        <zip>D7</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380003</name>
      <address>
        <city>Arezzo</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380004</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380005</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380009</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380007</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380006</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380011</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380002</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380001</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380008</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528002</name>
      <address>
        <city>Breda</city>
        <zip>4818CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528007</name>
      <address>
        <city>Enschede</city>
        <zip>7545KZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528003</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528005</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528004</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 578001</name>
      <address>
        <city>GrÃ¥lum</city>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 578002</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724004</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724003</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826001</name>
      <address>
        <city>Sutton</city>
        <zip>SM25PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Iceland</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

